Biogen Total Assets 2006-2021 | BIIB

Biogen total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Biogen total assets for the quarter ending September 30, 2021 were $23.807B, a 4.52% decline year-over-year.
  • Biogen total assets for 2020 were $24.619B, a 9.6% decline from 2019.
  • Biogen total assets for 2019 were $27.234B, a 7.69% increase from 2018.
  • Biogen total assets for 2018 were $25.289B, a 6.92% increase from 2017.
Biogen Annual Total Assets
(Millions of US $)
2020 $24,619
2019 $27,234
2018 $25,289
2017 $23,653
2016 $22,877
2015 $19,505
2014 $14,315
2013 $11,863
2012 $10,130
2011 $9,050
2010 $8,092
2009 $8,552
2008 $8,479
2007 $8,629
2006 $8,553
2005 $8,382
Biogen Quarterly Total Assets
(Millions of US $)
2021-09-30 $23,807
2021-06-30 $24,470
2021-03-31 $23,855
2020-12-31 $24,619
2020-09-30 $24,934
2020-06-30 $25,512
2020-03-31 $26,119
2019-12-31 $27,234
2019-09-30 $27,484
2019-06-30 $26,288
2019-03-31 $26,446
2018-12-31 $25,289
2018-09-30 $25,492
2018-06-30 $23,953
2018-03-31 $26,090
2017-12-31 $23,653
2017-09-30 $23,073
2017-06-30 $21,759
2017-03-31 $21,196
2016-12-31 $22,877
2016-09-30 $22,105
2016-06-30 $21,515
2016-03-31 $20,675
2015-12-31 $19,505
2015-09-30 $20,728
2015-06-30 $16,759
2015-03-31 $15,219
2014-12-31 $14,315
2014-09-30 $13,704
2014-06-30 $12,918
2014-03-31 $12,230
2013-12-31 $11,863
2013-09-30 $11,250
2013-06-30 $10,842
2013-03-31 $10,165
2012-12-31 $10,130
2012-09-30 $9,631
2012-06-30 $9,162
2012-03-31 $9,114
2011-12-31 $9,050
2011-09-30 $8,802
2011-06-30 $8,622
2011-03-31 $8,294
2010-12-31 $8,092
2010-09-30 $7,394
2010-06-30 $7,502
2010-03-31 $8,217
2009-12-31 $8,552
2009-09-30 $9,026
2009-06-30 $8,777
2009-03-31 $8,575
2008-12-31 $8,479
2008-09-30 $8,535
2008-06-30 $8,173
2008-03-31 $8,171
2007-12-31 $8,629
2007-09-30 $7,816
2007-06-30 $8,936
2007-03-31 $8,710
2006-12-31 $8,553
2006-09-30 $8,187
2006-06-30 $8,340
2006-03-31 $8,524
2005-12-31 $8,382
2005-09-30 $8,315
2005-06-30 $8,268
2005-03-31 $9,063
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $32.892B $13.445B
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90